9 results
2021 ACR/VF Guidelines for Management of Giant Cell Arteritis (GCA)

#GiantCell #Arteritis #GCA #ACR2021 #Management #rheumatology #algorithm
2021 ACR/VF Guidelines ... for Management ... of Giant Cell Arteritis ... #GCA #ACR2021 # ... #algorithm #vasculitis
Vasculitis Management - ACR/VF 2021 Guidelines for Treatment & Management
 • Giant Cell Arteritis (GCA)
 •
Vasculitis Management ... - ACR/VF 2021 Guidelines ... #Management #Treatment ... #ACR2021 #Guidelines ... #algorithm #rheumatology
Giant Cell Arteritis (GCA) - Vasculitis Management Algorithm - ACR/VF 2021 Guidelines
 • Visual Symptoms/Loss or
Giant Cell Arteritis ... Management Algorithm ... - ACR/VF 2021 Guidelines ... #Management #Treatment ... #ACR2021 #Guidelines
2021 ACR/VF Guidelines for Management of Takayasu Arteritis (TAK)

#Takayasu #Arteritis #TAK #ACR2021 #Management #rheumatology #algorithm #vasculitis
2021 ACR/VF Guidelines ... for Management ... of Takayasu Arteritis ... #TAK #ACR2021 # ... #algorithm #vasculitis
Polyarteritis Nodosa (PAN) - Vasculitis Management Algorithm - ACR/VF 2021 Guidelines
 • Severe Disease → Remission
Nodosa (PAN) - Vasculitis ... Management Algorithm ... - ACR/VF 2021 Guidelines ... #Management #Treatment ... #ACR2021 #Guidelines
Takayasu's Arteritis (TAK) - Vasculitis Management Algorithm - ACR/VF 2021 Guidelines
 • Active TAK not on
Takayasu's Arteritis ... Management Algorithm ... - ACR/VF 2021 Guidelines ... #Vasculitis #Management ... #Treatment #ACR2021
Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) - ANCA Vasculitis Management Algorithm - ACR/VF 2021
Management Algorithm ... - ACR/VF 2021 Guidelines ... #Management #Treatment ... #ACR2021 #Guidelines ... #algorithm #rheumatology
Eosinophilic Granulomatosis with Polyangiitis (EGPA) - ANCA Vasculitis Management Algorithm - ACR/VF 2021 Guidelines
 • Active
(EGPA) - ANCA Vasculitis ... Management Algorithm ... - ACR/VF 2021 Guidelines ... #Management #Treatment ... #ACR2021 #Guidelines
Sjogren's Syndrome Overview

Epidemiology:
• F > M: 9:1
• 5-6th Decades (can be any age)

Autoimmune exocrinopathy multisystemic disease
, INC risk PE, Pulmonary ... Arthralgia and Arthritis ... Adenocarcinoma Treatment ... lubricants • Pharmacologic ... Rheumatology #Diagnosis #Management